Chile is South America's most stable pharmaceutical market and ranks among the region's highest in per-capita healthcare spending. Valued at over $4 billion USD, the Chilean pharma market benefits from a strong institutional framework, a well-educated patient population, and a dual healthcare system that divides coverage between FONASA (Fondo Nacional de Salud) — the public insurer covering approximately 80% of the population — and ISAPRE (Instituciones de Salud Previsional), the private health insurance system serving higher-income segments.
ISP (Instituto de Salud Pública) is Chile's primary pharmaceutical regulator, with ANAMED (Agencia Nacional de Medicamentos) operating as its dedicated medicines regulatory division. ANAMED oversees drug registration, bioequivalence requirements, and clinical trial authorisation. MINSAL (Ministerio de Salud) sets national health policy and manages FONASA. Health technology assessment is conducted through ETESA (Evaluación de Tecnologías Sanitarias), which informs reimbursement and formulary decisions under the AUGE/GES guaranteed health conditions framework.
Santiago is Chile's dominant pharmaceutical hub, housing multinational affiliates, private hospital groups, and leading research universities. The Chilean market is characterised by high patient compliance, a growing chronic disease burden (cardiovascular, diabetes, oncology), and strong demand for innovative therapies. The right healthcare market research partner in Chile must combine ISP/ANAMED regulatory knowledge, FONASA/ISAPRE system fluency, bilingual Spanish-English research capability, and access to physician panels across Santiago and Chile's key regional cities.